Ramzi Hamouche

Heme-Onc Fellow | PGY4 @Uconn

[Toni Choueiri, MD @DrChoueiri]

JUST IN and via @Merck + @moderna_tx: A landmark moment for cancer immunotherapy. 🎯

Phase 3 INTerpath-001 is positive: the individualized mRNA neoantigen therapy intismeran (V940/mRNA-4157) + pembrolizumab significantly improved both RFS/DMFS vs pembrolizumab alone after resection of high-risk melanoma.

For years, the idea of designing a treatment around the unique mutations of each patient’s tumor seemed aspirational. Now we have the first positive Phase 3 trial (N=1137) of an individualized neoantigen therapy—and of an mRNA-based cancer therapy.

Personalized cancer vaccines are moving from promise to reality.

Now we need to see the magnitude of benefit, durability, and ultimately OS. But today is an important day for the field—and hopefully for our patients. 👏

Congrats to #CathyWu @DanaFarber for her trailblazing research that is materializing in tangible outcomes! At @DanaFarber_GU we are closely working with Cathy + @DFCI_NeoVax team on several GU protocols, after our @Nature work with @BraunMDPhD et al (https://t.co/BdbKJqMKOw)

https://t.co/Akd0XQt3ml

[Ramzi Hamouche @ramzi_hamouche]

Grateful for the opportunity to present our work at #ASH2023 under the mentorship of Dr. Francine Foss and @tarsheen2 . Also thankful for the guidance I received from @mirzasumab and @DiMengyang .
@YaleIMed @YWIMRP @YaleHemOnc

[Yale Cancer Center @YaleCancer]

Join us starting at 5:30pm PST/8:30pm EST in Halls
G-H, as 19 of our experts in #hematology present during today's Poster Session at #ASH23 @SmilowCancer @YaleHematology @MinaXu7 @ramzi_hamouche @johnvaughnmd @BarNoffar @SatokoItoMDPhD @sfhYALE @JMStempel @ketzer_franz @WaldronCJ

[Ramzi Hamouche @ramzi_hamouche]

@DayanaNasr Best of luck my friend!

[Yale Hematology Oncology Fellows @YaleHemOnc]

👋 Hello from our fellows and residents at the @ASTCT @CIBMTR #Tandem23 meeting! Kudos to Dr. Mirza, Dr. Di, and Dr. Hamouche for presenting their research on reduced intensity conditioning for allo transplants in patients with T-cell lymphoma. Strong work! ⭐️⭐️⭐️⭐️⭐️